Psychological distress during puerperium: A novel therapeutic approach using S-adenosylmethionine

Cerutti, R.; Sichel, M P; Perin, M.; Grussu, Pietro; Zulian, O.

doi:10.1016/s0011-393x(05)80742-8

Cited by 29 publications

(11 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This fairly exhaustive meta-analysis, excluded 2 potentially informative studies comparing SAMe against TCAs (50,67) due to insufficient statistical description, and one (64) because the authors were unable to obtain the paper. Regarding placebo comparisons, Cerutti et al (49) was excluded because it covered postpartum depression. Fazio et al (32) and Agnoli et al (35) were excluded because their data were covered in other papers.…”

Section: Resultsmentioning

confidence: 99%

<em>S</em>-Adenosylmethionine (SAMe) for Neuropsychiatric Disorders

Sharma¹,

Gerbarg²,

Bottiglieri³

et al. 2017

J. Clin. Psychiatry

122

View full text Add to dashboard Cite

Objective A systematic review on S-adenosylmethionine (SAMe) for treatment of neuropsychiatric conditions and co-morbid medical conditions. Data Sources Searches were conducted between 7/15/2015 and 9/28/2016 by combining search terms for SAMe (s-adenosyl methionine or s-adenosyl-l-methionine) with terms for relevant disease states including (major depressive disorder, MDD, depression, perinatal depression, human immunodeficiency virus, HIV, Parkinson's, Alzheimer's, dementia, anxiety, Schizophrenia, psychotic, 22q11.2, substance abuse, fibromyalgia, osteoarthritis, hepatitis, or cirrhosis). Additional studies were identified from prior literature. Ongoing clinical trials were identified through clinical trial registries. Study Selection Of the 174 records retrieved, 21 were excluded, as they were not original investigations. An additional 21 records were excluded, for falling outside of the scope of this review. Of the 132 studies included in this review, 115 were clinical trials and 17 were preclinical studies. Data Extraction A wide range of studies was included in this review in order to capture information that would be of interest to psychiatrists in clinical practice. Results This review of SAMe in the treatment of major depressive disorder found promising but limited evidence of efficacy and safety to support the use of SAMe as a monotherapy and as an augmentation for other antidepressants. Additionally, preliminary evidence suggests that SAMe may ameliorate symptoms in certain neurocognitive, substance use and psychotic disorders and co-morbid medical conditions. Conclusions SAMe holds promise as a treatment for multiple neuropsychiatric conditions, but the body of evidence has limitations. The encouraging findings support further study of SAMe in both psychiatric and co-morbid medical illnesses.

show abstract

Section: Resultsmentioning

confidence: 99%

<em>S</em>-Adenosylmethionine (SAMe) for Neuropsychiatric Disorders

Sharma¹,

Gerbarg²,

Bottiglieri³

et al. 2017

J. Clin. Psychiatry

122

View full text Add to dashboard Cite

show abstract

“…There is a proposal for a systematic review of antidepressant treatment of PND 17 , but to date, there is only one published comprehensive review of the treatment of PND 18 . This comprehensive literature review identified 26 published articles, however only four of these studies addressed antidepressant treatment 19,20,21,16 , and all exhibited methodological flaws.. Roy et al 19 successfully treated 4 women with fluoxetine, however this study was limited by a small sample size. Stowe et al 20 carried out an open-label trial of 26 women with DSM-IV postpartum major depression that occurred within 6 months of childbirth and treated the women with Sertraline.…”

Section: Introductionmentioning

confidence: 99%

“…Cerruti et al 21 carried out a two phase trial treating 'postpartum psychological distress' with 1600 mg oral S-adenosylmethionine (SAMe) daily from day 2 to day 30 postpartum. Phase one was a double-blind RCT in which 60 women whose scores on the Italian version of Kellner's Symptom Questionnaire (KSQ; Fava et al, 1983) indicated that they were psychologically distressed, were randomly allocated to treatment with SAMe or placebo.…”

Section: Introductionmentioning

confidence: 99%

Women's views of antidepressants in the treatment of postnatal depression

Boath

Bradley

Henshaw

2004

Journal of Psychosomatic Obstetrics & Gynecology

View full text Add to dashboard Cite

Little research has been carried out on the treatment of postnatal depression and clinicians must currently rely on general recommendations for the use of antidepressants. Antidepressant medication as the main treatment for depression in general practice has been shown to be effective when used as prescribed. However, research has shown that depressed patients consistently receive either no medication or consistently low doses of medication. This study will investigate women's experiences of taking antidepressant medication for postnatal depression. Thirty-five women with a clinical diagnosis of postnatal depression who had been prescribed antidepressant medication completed a questionnaire detailing their experiences of taking medication. Four open-ended questions and responses were discussed with the women. Of the 35 women who were prescribed medication, 4 chose not to take it because they were breast-feeding. Twenty of the women described finding medication helpful. Although only 4 women directly reported not taking antidepressants as prescribed, the comments made by a further 9 women suggest that compliance may have been poor. This study suggests a need to improve information about medication for postnatal depression. If this information is not provided, women are likely to continue to self-manage medication at a dosage that may be clinically ineffective.

show abstract

“…In a randomized clinical study of 30 women with postpartum depression, 1600 mg/day of S-adenosylmethionine resulted in a 70% reduction in symptoms of depression and anxiety compared with a 50% reduction in the placebo group by day 30 54. S-adenosylmethionine is safe to use during pregnancy and breast-feeding.…”

Section: Dietary Supplements As Cam Therapiesmentioning

confidence: 99%

Mood disorders and complementary and alternative medicine: a literature review

Qureshi¹,

Al-Bedah²

2013

NDT

125

View full text Add to dashboard Cite

Mood disorders are a major public health problem and are associated with considerable burden of disease, suicides, physical comorbidities, high economic costs, and poor quality of life. Approximately 30%–40% of patients with major depression have only a partial response to available pharmacological and psychotherapeutic interventions. Complementary and alternative medicine (CAM) has been used either alone or in combination with conventional therapies in patients with mood disorders. This review of the literature examines evidence-based data on the use of CAM in mood disorders. A search of the PubMed, Medline, Google Scholar, and Quertile databases using keywords was conducted, and relevant articles published in the English language in the peer-reviewed journals over the past two decades were retrieved. Evidence-based data suggest that light therapy, St John’s wort, Rhodiola rosea, omega-3 fatty acids, yoga, acupuncture, mindfulness therapies, exercise, sleep deprivation, and S-adenosylmethionine are effective in the treatment of mood disorders. Clinical trials of vitamin B complex, vitamin D, and methylfolate found that, while these were useful in physical illness, results were equivocal in patients with mood disorders. Studies support the adjunctive role of omega-3 fatty acids, eicosapentaenoic acid, and docosahexaenoic acid in unipolar and bipolar depression, although manic symptoms are not affected and higher doses are required in patients with resistant bipolar depression and rapid cycling. Omega-3 fatty acids are useful in pregnant women with major depression, and have no adverse effects on the fetus. Choline, inositol, 5-hydroxy-L-tryptophan, and N-acetylcysteine are effective adjuncts in bipolar patients. Dehydroepiandrosterone is effective both in bipolar depression and depression in the setting of comorbid physical disease, although doses should be titrated to avoid adverse effects. Ayurvedic and homeopathic therapies have the potential to improve symptoms of depression, although larger controlled trials are needed. Mind-body-spirit and integrative medicine approaches can be used effectively in mild to moderate depression and in treatment-resistant depression. Currently, although CAM therapies are not the primary treatment of mood disorders, level 1 evidence could emerge in the future showing that such treatments are effective.

show abstract

Psychological distress during puerperium: A novel therapeutic approach using S-adenosylmethionine

Cited by 29 publications

References 34 publications

<em>S</em>-Adenosylmethionine (SAMe) for Neuropsychiatric Disorders

<em>S</em>-Adenosylmethionine (SAMe) for Neuropsychiatric Disorders

Women's views of antidepressants in the treatment of postnatal depression

Mood disorders and complementary and alternative medicine: a literature review

Contact Info

Product

Resources

About